Market Cap: $1.55B
Innoviva (Ticker: INVA) makes significant advances in its biotechnology strategy through the launch of its clinical-stage subsidiary, Nortiva Bio. This new entity focuses on the LYNX long-acting oral…
Innoviva (Ticker: INVA) navigates a critical transition with strategic management changes and a focus on product development. Management Restructure Signals Strategic Shift The biopharmaceutical compa…
